SCHEMBL20161540

SCHEMBL20161540

CN1CCN(C(=O)CCOCCOCCOCCOCCNC(=O)CCCCC2SCC3NC(=O)NC32)CC1

nearest known ligand 0.62

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
F2 P00734 2/20 0.62
PRSS1 P07477 2/20 0.62
PRSS2 P07478 2/20 0.62
PRSS3 P35030 2/20 0.62
TPSAB1 Q15661 2/20 0.62
FOLH1 Q04609 3/20 0.59
PKM P14618 2/20 0.59
NOXO1 Q8NFA2 1/20 0.58
TDP1 Q9NUW8 2/20 0.56
DPP8 Q6V1X1 6/20 0.54
DPP9 Q86TI2 6/20 0.54
HSP90AB1 P08238 1/20 0.53
PLG P00747 1/20 0.52
L3MBTL3 Q96JM7 1/20 0.52
CA12 O43570 1/20 0.50
CA1 P00915 1/20 0.50
CA2 P00918 1/20 0.50
CA9 Q16790 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23365917 0.91 F2 (0.63) F2PRSS1PRSS2PRSS3TPSAB1
SCHEMBL19261534 0.91 F2 (0.60) F2PRSS1PRSS2PRSS3TPSAB1
SCHEMBL23365916 0.91 F2 (0.60) F2PRSS1PRSS2PRSS3TPSAB1
SCHEMBL4968230 0.88 F2 (0.73) F2PRSS1PRSS2PRSS3TPSAB1
SCHEMBL19751698 0.88 F2 (0.73) F2PRSS1PRSS2PRSS3TPSAB1
SCHEMBL15216220 0.88 F2 (0.73) F2PRSS1PRSS2PRSS3TPSAB1
SCHEMBL19017236 0.88 F2 (0.73) F2PRSS1PRSS2PRSS3TPSAB1
SCHEMBL30574542 0.87 TDP1 (0.71) F2PRSS1PRSS2PRSS3TPSAB1
SCHEMBL20161403 0.87 CA12 (0.60) F2PRSS1PRSS2PRSS3TPSAB1
SCHEMBL15786481 0.86 F2 (0.56) F2PRSS1PRSS2PRSS3TPSAB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11897874-B2 Compounds and methods for modulating Interleukin-2-inducible T-cell kinase CORVUS PHARMACEUTICALS, INC. (US) 2024-02-13 US disclosed
EP-3534899-B1 COMPOUNDS AND METHODS FOR MODULATING INTERLEUKIN-2-INDUCIBLE T-CELL KINASE CORVUS PHARMACEUTICALS INC (US) 2022-06-01 EP disclosed
US-11008314-B2 Compounds and methods for modulating interleukin-2-inducible t-cell kinase CORVUS PHARMACEUTICALS, INC. (US) 2021-05-18 US disclosed
WO-2018089261-A2 COMPOUNDS AND METHODS FOR MODULATING INTERLEUKIN-2-INDUCIBLE T-CELL KINASE CORVUS PHARMACEUTICALS, INC. (US) 2018-05-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11008314-B2 Compounds and methods for modulating interleukin-2-inducible t-cell kinase IL2, NFATC1, IL2RA F2 4581/4885PRSS1 3218/4885PRSS2 2869/4885
US-11897874-B2 Compounds and methods for modulating Interleukin-2-inducible T-cell kinase IL2, NFATC1, IL2RA F2 4581/4885PRSS1 3218/4885PRSS2 2869/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.